NASDAQ : CMPX
Compass Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.7698 USD (Oct 30, 2026, 3:19 PM EDT) · Market cap 138.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 140.18M |
| Enterprise Value | -30.07M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 180.09M |
| Shares Outstanding | 180.09M |
| Shares Change (YoY) | +31.82% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 5.86% |
| Owned by Institutions (%) | 78.53% |
| Float | 132.42M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.22 |
| Quick Ratio | 11.15 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -56.66% |
| Return on Assets (ROA) | -33.03% |
| Return on Invested Capital (ROIC) | -36.36% |
| Return on Capital Employed (ROCE) | -46.59% |
| Weighted Average Cost of Capital (WACC) | 8.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 39 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -79.19% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 27.28 |
| Average Volume (20 Days) | 3,862,388 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 41.84M |
| Short Previous Month | 40.36M |
| Short % of Shares Out | 23.24% |
| Short % of Float | 31.60% |
| Short Ratio (days to cover) | 6.08 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.09M |
| Pretax Income | -73.45M |
| Net Income | -73.45M |
| EBITDA | -81.01M |
| EBIT | -81.09M |
| Earnings Per Share (EPS) | -$0.40 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 179.88M |
| Total Debt | 9.63M |
| Net Cash | 170.25M |
| Net Cash Per Share | $0.95 |
| Equity (Book Value) | 166.05M |
| Book Value Per Share | 0.92 |
| Working Capital | 164.76M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -56.11M |
| Capital Expenditures | -265,000 |
| Depreciation & Amortization | 72,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -56.38M |
| FCF Per Share | -$0.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.82% |
| Shareholder Yield | -31.82% |
| Earnings Yield | -51.88% |
| FCF Yield | -39.80% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.46 |
| Price Target Difference | 600.80% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |